Research Summary

Since joining the GU medical oncology program at UCSF, my efforts have been directed towards prostate cancer, particularly focusing on metastatic hormone sensitive prostate cancer. Continuous combined androgen deprivation is the mainstay of treatment for patients with mHSPC with several trials demonstrating an improvement in overall survival (OS) with the addition of second-generation antiandrogens to ADT. The broad spectrum of ADT associated toxicities, the potential to delay castrate resistance and decrease treatment costs, led to the evaluation of intermittent ADT (IAD) and it is non-inferior to CAD in terms of survival benefit, and is associated with an improvement in quality of life (QOL). A recent landmark survival analysis of the CHAARTED data showed that a PSA of ≤ 0.2 ng/mL at 7 months is prognostic for longer OS with ADT for mHSPC. Currently, there are no guidelines regarding the use of intermittent intensified ADT in patients with mHSPC. We hypothesize that intensified ADT can be effectively used in an intermittent fashion in men with low volume mHSPC who have an exceptional response with PSA
Given my specific research interest in mHSPC, I look forward to actively participating in the prostate program and developing therapeutic interventions to improve outcomes.


Kempegowda Institute of Medical Sciences, Bangalore, India MBBS 06/2009
State University of New York at Buffalo, Buffalo, NY Resident 06/2014 Internal Medicine
Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY Phase I 06/2015
University of Chicago, Chicago, IL Fellow 08/2018 Hematology/Oncology
AACR/ASCO Workshop on Methods in Clinical Cancer Research 08/2018

Honors & Awards

  • 2013
    Department of Medicine Research Award for Basic Sciences Research, State University of New York at Buffalo
  • 2014
    Dexter S. Levy Memorial Award for commitment to teaching, dedication to patients and support of colleagues, State University of New York at Buffalo
  • 2015
    Thomas F. Frawley Research Fellowship Award, State University of New York at Buffalo
  • 2018
    Conquer Cancer Foundation of ASCO/Frances A. Shepherd, MD, Endowed Merit Award in Lung Cancer, American Society of Clinical Oncology
  • 2018
    Young Investigator Travel Award, IASLC, IASLC, World Conference on Lung Cancer

Selected Publications

  1. de Kouchkovsky I, Zhang L, Philip EJ, Wright F, Kim DM, Natesan D, Kwon D, Ho H, Ho S, Chan E, Porten SP, Wong AC, Desai A, Huang FW, Chou J, Oh DY, Pruthi RS, Fong L, Small EJ, Friedlander TW, Koshkin VS. TERT promoter mutations and other prognostic factors in patients with advanced urothelial carcinoma treated with an immune checkpoint inhibitor. J Immunother Cancer. 2021 05; 9(5).  View on PubMed
  2. Kwon DH, Chou J, Yip SM, Reimers MA, Zhang L, Wright F, Dhawan MS, Borno HT, Desai A, Aggarwal RR, Wyatt AW, Small EJ, Alva AS, Chi KN, Feng FY, Koshkin VS. Differential treatment outcomes in BRCA1/2-, CDK12-, and ATM-mutated metastatic castration-resistant prostate cancer. Cancer. 2021 Jun 15; 127(12):1965-1973.  View on PubMed
  3. Borno HT, Kuo Lin T, Odisho AY, Desai A, Koshkin V, Werner K, Legaspi N, Bucknor M, Bell A, Zhang S, Hope TA. Evaluating determinants of receipt of molecular imaging in biochemical recurrent prostate cancer. Cancer Med. 2021 01; 10(1):62-69.  View on PubMed
  4. Barata P, Hatton W, Desai A, Koshkin V, Jaeger E, Manogue C, Cotogno P, Light M, Lewis B, Layton J, Sartor O, Basu A, Kilari D, Emamekhoo H, Bilen MA. Outcomes With First-Line PD-1/PD-L1 Inhibitor Monotherapy for Metastatic Renal Cell Carcinoma (mRCC): A Multi-Institutional Cohort. Front Oncol. 2020; 10:581189.  View on PubMed
  5. Motzer RJ, Jonasch E, Boyle S, Carlo MI, Manley B, Agarwal N, Alva A, Beckermann K, Choueiri TK, Costello BA, Derweesh IH, Desai A, George S, Gore JL, Haas N, Hancock SL, Kyriakopoulos C, Lam ET, Lau C, Lewis B, Madoff DC, McCreery B, Michaelson MD, Mortazavi A, Nandagopal L, Pierorazio PM, Plimack ER, Ponsky L, Ramalingam S, Shuch B, Smith ZL, Somer B, Sosman J, Dwyer MA, Motter AD. NCCN Guidelines Insights: Kidney Cancer, Version 1.2021. J Natl Compr Canc Netw. 2020 09; 18(9):1160-1170.  View on PubMed
  6. Desai A, Small EJ. Treatment of advanced renal cell carcinoma patients with cabozantinib, an oral multityrosine kinase inhibitor of MET, AXL and VEGF receptors. Future Oncol. 2019 Jul; 15(20):2337-2348.  View on PubMed

Go to UCSF Profiles, powered by CTSI